

# McKesson Corporation (MCK)

Updated December 1<sup>st</sup>, 2020 by Josh Arnold

#### Key Metrics

| Current Price:       | \$179 | 5 Year CAGR Estimate:               | 8.9%  | Market Cap:               | \$29 B   |
|----------------------|-------|-------------------------------------|-------|---------------------------|----------|
| Fair Value Price:    | \$197 | 5 Year Growth Estimate:             | 6.0%  | Ex-Dividend Date:         | 11/30/20 |
| % Fair Value:        | 91%   | 5 Year Valuation Multiple Estimate: | 1.9%  | Dividend Payment Date:    | 01/04/21 |
| Dividend Yield:      | 0.9%  | 5 Year Price Target                 | \$263 | Years Of Dividend Growth: | 13       |
| Dividend Risk Score: | А     | Retirement Suitability Score:       | С     | Last Dividend Increase:   | 2.4%     |

## **Overview & Current Events**

McKesson Corporation traces its lineage to 1833 when its founders began to offer wholesale chemicals and pharmaceuticals in New York City. In the 187 years since, McKesson has grown into a powerhouse in the pharmaceutical and medical distribution industry and today, generates nearly \$240 billion in annual revenue and trades with a \$29 billion market capitalization.

McKesson reported second quarter earnings on November 3<sup>rd</sup>, 2020 with results coming in much better than expected on the top and bottom lines. Revenue was up 6% year-over-year to nearly \$61 billion, driven by growth in the US Pharmaceutical segment, which was attributable to market growth and higher volumes from retail national account customers. This was partially offset by conversions from branded drugs to generics.

Adjusted earnings-per-share came to \$4.80, up 33% from \$3.60 in the year-ago period. This was driven by a lower share count, a lower tax rate, and growth in the company's Medical-Surgical Solutions segment.

McKesson raised its guidance for adjusted diluted earnings-per-share for this year from \$14.70 to \$15.50 to a new range of \$16.00 to \$16.50. The company believes it will continue to see strong execution and improvement in volumes into the second half of the year. We've boosted our estimate of earnings-per-share to \$16.40 based on strong Q2 results and raised guidance.

| Year                | 2011   | 2012   | 2013   | 2014   | 2015    | 2016   | 2017    | 2018    | 2019    | 2020    | 2021    | 2026    |
|---------------------|--------|--------|--------|--------|---------|--------|---------|---------|---------|---------|---------|---------|
| EPS                 | \$5.00 | \$5.83 | \$6.33 | \$8.35 | \$11.11 | \$9.84 | \$11.61 | \$12.62 | \$13.57 | \$14.95 | \$16.40 | \$21.95 |
| DPS                 | \$0.72 | \$0.80 | \$0.80 | \$0.92 | \$0.96  | \$1.08 | \$1.12  | \$1.30  | \$1.51  | \$1.62  | \$1.68  | \$2.36  |
| Shares <sup>1</sup> | 252    | 235    | 227    | 231    | 232     | 225    | 211     | 202     | 191     | 173     | 173     | 155     |

### Growth on a Per-Share Basis

McKesson's earnings-per-share history is quite robust, having grown nearly every year in the past decade. Indeed, McKesson has managed to average more than 10% earnings-per-share growth annually over this time frame through organic revenue growth and many acquisitions. We do not believe that sort of growth is likely for the longer term as McKesson has grown much larger. As a result, it seems to have neared a plateau on operating margins and revenue growth, but we do still see 6% annual earnings-per-share growth as sustainable moving forward.

McKesson can achieve this result largely via revenue gains, which we forecast will be in the area of 3% to 5% for the foreseeable future. It continues to acquire growth in bolt-on acquisitions with companies that supplement its current offerings, a strategy that is unlikely to change. Margins have been flat for some time, so we expect that will continue. We note that the first quarter saw McKesson deviate from this, but it was due to extraordinary circumstances resulting from COVID-19.

The buyback should continue to meaningfully reduce the float over time, which we see as a key driver of earnings-pershare growth. We remain somewhat cautious due to an increasingly hostile regulatory environment for drug wholesalers

<sup>1</sup> Share count in millions

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



# McKesson Corporation (MCK)

#### Updated December 1<sup>st</sup>, 2020 by Josh Arnold

like McKesson. In addition, constant pressure on pricing from regulators, as well as strong generic conversion are headwinds. However, recent results have been quite supportive of long-term growth, including Q2 and guidance.

The dividend has never been a priority for McKesson and that is not likely to change anytime soon. We see the payout rising from today's \$1.68 to \$2.36 in five years, but the dividend remains just a small fraction of earnings.

#### Valuation Analysis

| Year      | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | Now  | 2026 |
|-----------|------|------|------|------|------|------|------|------|------|------|------|------|
| Avg. P/E  | 13.6 | 13.8 | 14.9 | 16.8 | 17.9 | 20.1 | 14.1 | 12.0 | 9.7  | 9.3  | 10.9 | 12.0 |
| Avg. Yld. | 1.1% | 1.0% | 0.8% | 0.7% | 0.5% | 0.5% | 0.7% | 0.5% | 1.1% | 1.2% | 0.9% | 0.9% |

The stock's price-to-earnings ratio has ebbed and flowed in the past decade but today, at 10.9 times earnings, it appears to still be undervalued relative to its historical norm. We see fair value as 12 times earnings and thus, McKesson offers a reasonable value to prospective shareholders in our view. This could provide a small tailwind to total returns over the next five years if the stock's valuation reverts to more normalized levels. The yield should remain about where it is for the foreseeable future.

# Safety, Quality, Competitive Advantage, & Recession Resiliency


| Year   | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2026 |
|--------|------|------|------|------|------|------|------|------|------|------|------|------|
| Payout | 13%  | 13%  | 13%  | 11%  | 9%   | 11%  | 10%  | 10%  | 11%  | 11%  | 10%  | 11%  |

The payout ratio will remain very low barring a material strategic shift, which we are not forecasting. Instead, McKesson will almost certainly continue to boost earnings-per-share by reducing the float, as it did once again in fiscal 2020.

Its competitive advantage is in its willingness to adapt and shift to the changing needs of its customers, its willingness to buy growth and its immense scale, which affords purchasing power. McKesson should hold up well during this recession given its product assortment that offers healthcare consumers things they need, and not discretionary items.

## Final Thoughts & Recommendation

McKesson continues to look attractive as it offers a decent growth outlook, a robust share repurchase program and a valuation that is still under our view of fair value. We are forecasting 8.9% annual total returns going forward, consisting of the current 0.9% yield, 6% earnings-per-share growth and a tailwind from a rising valuation. That would make McKesson attractive for investors seeking growth or value, but its low yield would make it unattractive for investors seeking high levels of income. Due to the somewhat higher valuation, we're moving McKesson back to a hold rating.



# Total Return Breakdown by Year

#### Click here to rate and review this research report. Your feedback is important to us.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



# McKesson Corporation (MCK)

Updated December 1<sup>st</sup>, 2020 by Josh Arnold

### **Income Statement Metrics**

| Year                    | 2011  | 2012  | 2013  | 2014  | 2015   | 2016   | 2017   | 2018   | 2019   | 2020   |
|-------------------------|-------|-------|-------|-------|--------|--------|--------|--------|--------|--------|
| Revenue (\$B)           | 112.1 | 122.3 | 122.2 | 137.4 | 179.0  | 190.9  | 198.5  | 208.4  | 214.3  | 231.1  |
| Gross Profit            | 5,970 | 6,402 | 6,881 | 8,352 | 11,411 | 11,416 | 11,271 | 11,184 | 11,754 | 12,023 |
| Gross Margin            | 5.3%  | 5.2%  | 5.6%  | 6.1%  | 6.4%   | 6.0%   | 5.7%   | 5.4%   | 5.5%   | 5.2%   |
| SG&A Exp.               | 3,529 | 3,727 | 4,110 | 5,388 | 7,901  | 7,379  | 7,447  | 8,138  | 8,403  | 9,168  |
| D&A Exp.                | 496   | 493   | 581   | 735   | 1,017  | 885    | 910    | 951    | 949    | 922    |
| <b>Operating Profit</b> | 2,034 | 2,273 | 2,338 | 2,507 | 3,118  | 3,645  | 3,483  | 2,921  | 3,280  | 2,759  |
| <b>Operating Margin</b> | 1.8%  | 1.9%  | 1.9%  | 1.8%  | 1.7%   | 1.9%   | 1.8%   | 1.4%   | 1.5%   | 1.2%   |
| Net Profit              | 1,202 | 1,403 | 1,338 | 1,263 | 1,476  | 2,258  | 5,070  | 67     | 34     | 900    |
| Net Margin              | 1.1%  | 1.1%  | 1.1%  | 0.9%  | 0.8%   | 1.2%   | 2.6%   | 0.0%   | 0.0%   | 0.4%   |
| Free Cash Flow          | 1,950 | 2,552 | 2,083 | 2,717 | 2,567  | 2,995  | 4,182  | 3,765  | 3,479  | 3,868  |
| Income Tax              | 505   | 514   | 587   | 757   | 815    | 908    | 1,614  | (53)   | 356    | 18     |

### **Balance Sheet Metrics**

| Year               | 2011   | 2012   | 2013   | 2014   | 2015   | 2016   | 2017   | 2018   | 2019   | 2020   |
|--------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Total Assets       | 30,886 | 33,093 | 34,786 | 51,759 | 53,870 | 56,523 | 60,969 | 60,381 | 59,672 | 61,247 |
| Cash & Equivalents | 3,612  | 3,149  | 2,456  | 4,193  | 5,341  | 4,048  | 2,783  | 2,672  | 2,981  | 4,015  |
| Acc. Receivable    | 7,982  | 8,562  | 8,683  | 12,169 | 13,117 | 14,519 | 14,602 | 14,349 | 14,941 | 17,201 |
| Inventories        | 9,225  | 10,073 | 10,335 | 12,986 | 14,296 | 15,335 | 15,278 | 16,310 | 16,709 | 16,734 |
| Goodwill & Int.    | 5,972  | 6,782  | 8,675  | 14,798 | 13,258 | 12,807 | 14,251 | 15,026 | 13,047 | 12,516 |
| Total Liabilities  | 23,666 | 26,262 | 27,716 | 41,441 | 45,785 | 47,515 | 49,696 | 50,324 | 51,385 | 55,938 |
| Accounts Payable   |        | 16,114 | 16,108 | 21,128 | 25,166 | 28,585 | 31,022 | 32,177 | 33,853 | 37,195 |
| Long-Term Debt     | 4,004  | 3,980  | 4,873  | 10,594 | 9,844  | 8,114  | 8,545  | 7,880  | 7,595  | 7,387  |
| Total Equity       | 7,220  | 6,831  | 7,070  | 8,522  | 8,001  | 8,924  | 11,095 | 9,804  | 8,094  | 5,092  |
| D/E Ratio          | 0.55   | 0.58   | 0.69   | 1.24   | 1.23   | 0.91   | 0.77   | 0.80   | 0.94   | 1.45   |

#### **Profitability & Per Share Metrics**

| Year                    | 2011       | 2012        | 2013       | 2014        | 2015        | 2016       | 2017   | 2018   | 2019    | 2020    |
|-------------------------|------------|-------------|------------|-------------|-------------|------------|--------|--------|---------|---------|
| <b>Return on Assets</b> | 4.1%       | 4.4%        | 3.9%       | 2.9%        | 2.8%        | 4.1%       | 8.6%   | 0.1%   | 0.1%    | 1.5%    |
| <b>Return on Equity</b> | 16.3%      | 20.0%       | 19.3%      | 16.2%       | 17.9%       | 26.7%      | 50.7%  | 0.6%   | 0.4%    | 13.7%   |
| ROIC                    | 11.4%      | 12.7%       | 11.8%      | 7.7%        | 7.6%        | 12.9%      | 27.4%  | 0.4%   | 0.2%    | 6.3%    |
| Shares Out.             | 252        | 235         | 227        | 231         | 232         | 225        | 211    | 202    | 191     | 173     |
| Revenue/Share           | 426.17     | 487.33      | 511.28     | 589.67      | 761.89      | 819.24     | 890.28 | 996.92 | 1,087.9 | 1,269.5 |
| FCF/Share               | 7.41       | 10.17       | 8.72       | 11.66       | 10.92       | 12.85      | 18.75  | 18.01  | 17.66   | 21.25   |
| Note: All figures in    | millions o | f U.S. Doll | ars unless | per share o | or indicate | d otherwis | se.    |        |         |         |

#### Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.